The completion of patient recruitment removes a key binary risk and de-risks the timeline to a potential blockbuster product. Traders should watch for top-line data in mid-2027 and any partnership or licensing announcements before then. The strong insider buying and RMAT designation support a positive outlook, but the long wait for data means near-term volatility may be limited.
MESO drugs
MESO drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 29 $15.55entry
- T+1 · 7mo ago +0.77%α −0.25% · $15.67
- T+5 · 7mo ago +1.67%α −1.44% · $15.81
- T+20 · 6mo ago −5.08%α −11.13% · $14.76
- T+60 · 4mo ago −1.54%α −5.65% · $15.31
Price Chart
How similar events traded
Executive Summary
Mesoblast announced that its Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain due to degenerative disc disease has completed patient recruitment. Top-line results are expected in mid-2027, with a potential FDA filing in Q3 2027. The trial targets a large U.S. market of over 7 million patients, and the drug has RMAT designation, enabling priority review.
Key Facts
- Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain has completed patient recruitment.
- Top-line results expected mid-CY2027; regulatory filing with FDA planned for Q3 CY2027.
- Rexlemestrocel-L has RMAT designation from FDA, providing priority review eligibility.
- Target indication: chronic low back pain due to degenerative disc disease, affecting over 7 million people in the U.S.
- Management estimates potential peak revenue >$10 billion with single-digit market penetration.
- Earlier Phase 3 trial (MSB-DR003) showed clinically meaningful pain reduction and opioid cessation for up to three years.
- Insider buying of $20.8M over the past 30 days (6 buys) aligns with positive sentiment.
Financial Impact
Potential peak revenue >$10 billion with single-digit market penetration; no current revenue from this product.
Risk Factors
- Phase 3 trial may fail to meet primary endpoint, leading to stock decline.
- Regulatory filing and approval are not guaranteed; FDA could request additional data.
- Long timeline to results (mid-2027) means no near-term revenue catalyst.
- Competition from other cell therapies or non-opioid pain treatments could limit market share.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283366 |
Track record
25 reports on MESO
6 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
- Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
- Oct 29, 202618d ago 6-K Bullish 6/10 No price data
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
- Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
- Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
- Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
- Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers